Hematological Changes in Newly Diagnosed Pulmonary Tuberculosis Patients on Standard Anti-TB Treatment Regimen and their Influence on Smear Conversion

https://doi.org/10.51867/ajernet.5.4.80

Authors

Keywords:

Anemia, Leukocytosis, Thrombocytosis

Abstract

Pulmonary tuberculosis (PTB) mortality remains high despite the availability of effective anti-TB therapy. Disease and treatment-associated hematological derangements at diagnosis and during therapy might contribute to this high TB mortality rate. This paper aims to determine hematological changes in newly diagnosed pulmonary tuberculosis patients on standard anti-TB treatment regimen and their influence on smear conversion. The study adopted a longitudinal design in which 55 newly diagnosed HIV negative PTB patients were followed up to the fifth month of anti-TB therapy. Blood samples (5ml) were collected for diagnosis during the second and fifth months and analyzed using automated HumaCount 5D hematology analyzer. Data was analyzed using Kruskal-wallis test with Dunns multiple comparisons test in Graph-Pad prism version 6.0. Throughout therapy, there was a statistically significant time-dependent decrease in median total white blood cell counts from 6.82x103/ uL at diagnosis to 5.87x103/ uL at the fifth month (P=0.0358). This decrease in total WBC count was majorly driven by significant decrease in the neutrophil numbers from 4.31x103/ uL at diagnosis to 2.97x103/ uL at the fifth month. The proportion of patients who had anemia at the fifth month of treatment increased compared to the second month post intensive phase. There was also a significant decrease in MCV, MCH and MCHC at the second month compared to diagnosis. Moreover, the median platelet count, MPV, PDW and PCT% decreased from 314x103/ uL, 8.9 fL, 10.4 fL and 0.273 at diagnosis to 232x103/ uL, 10.15 fL, 12.5 fL and 0.235 at the fifth month, respectively. High WBC count, high platelet count, low lymphocyte count and low HGB at the end of month two of therapy were shown to increase the likelihood of sputum non-conversion (OR-2.42 (95% Ci 2.07-2.82)), (OR-1.5 (95% Ci 1.01-2.22)), (OR-1 (95% Ci 1-1)) and (OR-2.58 (95% Ci 1.68-3.95)), respectively (P<0.05). A significant number of PTB patients presented with anemia, thrombocytosis and leukocytosis. The proportion of patients with anemia increased over time. The study recommends screening for hematological abnormalities in patients for tailored patient interventions for better clinical outcomes.

Dimensions

Aster, R. H., & Bougie, D. W. (2007). Drug-induced immune thrombocytopenia. New England Journal of Medicine, 357(6), 580-587. https://doi.org/10.1056/NEJMra066469 DOI: https://doi.org/10.1056/NEJMra066469

Balboa, L., Romero, M. M., Yokobori, N., Schierloh, P., Geffner, L., Basile, J. I., Musella, R. M., Abbate, E., de la Barrera, S., Sasiain, M. C., & Alemán, M. (2010). Mycobacterium tuberculosis impairs dendritic cell response by altering CD1b, DC-SIGN and MR profile. Immunology & Cell Biology, 88(7), 716-726. https://doi.org/10.1038/icb.2010.22 DOI: https://doi.org/10.1038/icb.2010.22

Bonsome, D. B. (2018). Evaluation of haematological parameters in the initial phase of anti-tuberculosis therapy in Yenagoa, Nigeria. Nigerian Del Med J, 1(4), 10-15.

de Martino, M., Lodi, L., Galli, L., & Chiappini, E. (2019). Immune response to Mycobacterium tuberculosis: A narrative review. Frontiers in Pediatrics, 7, 350. https://doi.org/10.3389/fped.2019.00350 DOI: https://doi.org/10.3389/fped.2019.00350

Fox, K. A., Kirwan, D. E., Whittington, A. M., Krishnan, N., Robertson, B. D., Gilman, R. H., López, J. W., Singh, S., Porter, J. C., & Friedland, J. S. (2018). Platelets regulate pulmonary inflammation and tissue destruction in tuberculosis. American Journal of Respiratory and Critical Care Medicine, 198(2), 245-255. https://doi.org/10.1164/rccm.201710-2102OC DOI: https://doi.org/10.1164/rccm.201710-2102OC

Global Tuberculosis Report. (2021, October 14). World Health Organization. Retrieved on 4 August 2024, from https://www.who.int/publications/i/item/9789240037021

Kassa, E., Enawgaw, B., Gelaw, A., & Gelaw, B. (2016). Effect of anti-tuberculosis drugs on hematological profiles of tuberculosis patients attending at University of Gondar Hospital, Northwest Ethiopia. BMC Hematology, 16(1), 1. https://doi.org/10.1186/s12878-015-0037-1 DOI: https://doi.org/10.1186/s12878-015-0037-1

Kirwan, D. E., Chong, D. L. W., & Friedland, J. S. (2021). Platelet activation and the immune response to tuberculosis. Frontiers in Immunology, 12, 631-696. https://doi.org/10.3389/fimmu.2021.631696

https://doi.org/10.3389/fimmu.2021.631696 DOI: https://doi.org/10.3389/fimmu.2021.631696

Ministry of Health Kenya. (2022). Annual TB report 2022. Retrieved July 20, 2022, from https://www.nltp.co.ke/reports/annual-reports/content/uploads/2022/07/DNTLDP_AnnualReport_2022_compressed.pdf

Ministry of Health, Republic of Kenya. (2021). Integrated guideline for tuberculosis, leprosy and lung disease. Retrieved October 4, 2022, from https://www.nltp.co.ke/wp-content/uploads/2022/02/Integrated-Guideline.pdf

Nagu, T. J., Spiegelman, D., Hertzmark, E., Aboud, S., Makani, J., Matee, M. I., Fawzi, W., & Mugusi, F. (2014). Anemia at the initiation of tuberculosis therapy is associated with delayed sputum conversion among pulmonary tuberculosis patients in Dar-es-Salaam, Tanzania. PloS One, 9(3), e91229. https://doi.org/10.1371/journal.pone.0091229 DOI: https://doi.org/10.1371/journal.pone.0091229

Obeagu, E., Ijeoma, O., Nwanjo, H., & Nwosu, D. (2019). Evaluation of haematological parameters of tuberculosis patients in Umuahia. European Journal of Pharmaceutical and Medical Research, 6(7), 693-699. https://www.ejpmr.com/home/abstract_id/5418

Ramarokoto, H., Randriamiharisoa, H., Rakotoarisaonina, A., Rasolovavalona, T., Rasolofo, V., Chanteau, S., Ralamboson, M., Cauchoix, B., & Rakotondramarina, D. (2002). Bacteriological follow-up of tuberculosis treatment: A comparative study of smear microscopy and culture results at the second month of treatment. The International Journal of Tuberculosis and Lung Disease, 6(10), 909-912.

Reta, B., Mohammed, A. E., Tesfaye Kiya, G., Adissu, W., & Shenkute, T. Y. (2023). Impact of anti-tuberculosis treatment on hematological parameters in newly diagnosed tuberculosis patients at Jimma town: A longitudinal prospective study. Annals of Medicine and Surgery, 85(8), 3887. https://doi.org/10.1097/MS9.0000000000001084 DOI: https://doi.org/10.1097/MS9.0000000000001084

Visentin, G. P., & Liu, C. Y. (2007). Drug-induced thrombocytopenia. Hematology/Oncology Clinics of North America, 21(4), 685-696. https://doi.org/10.1016/j.hoc.2007.06.005 DOI: https://doi.org/10.1016/j.hoc.2007.06.005

World Health Organization. (2017). Guidelines for treatment of drug-susceptible tuberculosis and patient care (2017 update). Geneva: World Health Organization.

World Health Organization. (2021, October 14). Global tuberculosis report. Retrieved August 4, 2024, from https://www.who.int/publications/i/item/9789240037021

Wu, T., Guo, S., Wang, J., Li, L., Xu, L., Liu, P., Ma, S., Zhang, J., Xu, L., & Luo, Y. (2011). Interaction between mannosylated lipoarabinomannan and dendritic cell-specific intercellular adhesion molecule-3 grabbing nonintegrin influences dendritic cells maturation and T cell immunity. Cellular Immunology, 272(1), 94-101. https://doi.org/10.1016/j.cellimm.2011.09.001 DOI: https://doi.org/10.1016/j.cellimm.2011.09.001

Yadav, A. M., Deshpande, N., Deshmukh, S., Kamble, H., & Dope, S. (2022). Study of haematological profile & changes in haematological profile caused by first-line antitubercular drugs in patients with pulmonary tuberculosis. Journal of Cardiovascular Disease Research, 13(4).

Yakar, F., Yildiz, N., Yakar, A., & Kılıçaslan, Z. (2013). Isoniazid- and rifampicin-induced thrombocytopenia. Multidisciplinary Respiratory Medicine, 8(1), 13. https://doi.org/10.1186/2049-6958-8-13 DOI: https://doi.org/10.1186/2049-6958-8-13

Published

2024-11-13

How to Cite

Mwilitsa, E., Raballah, E., & Kimoloi, S. (2024). Hematological Changes in Newly Diagnosed Pulmonary Tuberculosis Patients on Standard Anti-TB Treatment Regimen and their Influence on Smear Conversion. African Journal of Empirical Research, 5(4), 975–986. https://doi.org/10.51867/ajernet.5.4.80